Travis Mickle - Kempharm Chairman

KMPH -  USA Stock  

USD 10.75  0.24  2.18%

  Chairman
Dr. Travis C. Mickle, Ph.D., serves as Chairman of the Board, President, Chief Executive Officer of KemPharm, Inc. Dr. Mickle is a cofounder of our company and has served as a member of our board of directors since our inception in 2006 and chairman of our board of directors since November 2014. Dr. Mickle served as our president and chief scientific officer from 2006 to October 2010, and has served as our president and chief executive officer since October 2010. Prior to founding our company, Dr. Mickle spent five years with New River Pharmaceuticals, a specialty pharmaceutical company, where he was a senior research scientist from 2001 to 2002, the director of chemistry from 2002 to 2003 and the director of drug discovery and CMC from 2003 to 2005
Age: 44  Chairman Since 2014  Ph.D    
321 939 3416  http://kempharm.com
Mickle received his Ph.D. degree from the University of Iowa and his B.A. degree from Simpson College. Our board of directors believes that Dr. Mickle’s leadership of our company since its inception, knowledge of our company as founder and experience with pharmaceutical companies provides him with the qualifications and skills to serve as a director of our company.

Travis Mickle Latest Insider Activity

Tracking and analyzing the buying and selling activities of Travis Mickle against Kempharm stock is an integral part of due diligence when investing in Kempharm. Travis Mickle insider activity provides valuable insight into whether Kempharm is net buyers or sellers over its current business cycle. Note, Kempharm insiders must abide by specific rules, including filing SEC forms every time they buy or sell Kempharm'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Travis Mickle over a month ago via Macroaxis 
Kempharm exotic insider transaction detected
Travis Mickle over a year ago via Macroaxis 
KemPharm exotic insider transaction detected
Travis Mickle over a year ago via Macroaxis 
KemPharm exotic insider transaction detected
Travis Mickle over a year ago via Macroaxis 
KemPharm exotic insider transaction detected

Kempharm Management Efficiency

Kempharm has return on total asset (ROA) of 6.45 % which means that it generated profit of $6.45 on every $100 spent on asset. This is normal as compared to the sector avarege. Similarly, it shows return on stockholders equity (ROE) of (222.16) %, meaning that it created substantial loss on money invested by shareholders. Kempharm management efficiency ratios could be used to measure how well the company manages its routine affairs as well as how well it operates its assets and liabilities. The current Return on Average Equity is estimated to increase to 0.20, while Return on Average Assets are projected to decrease to (1.26) . Kempharm Assets Non Current are most likely to increase significantly in the upcoming years. The last year's value of Assets Non Current was reported at 2.83 Million. The current Asset Turnover is estimated to increase to 1.26, while Return on Average Assets are projected to decrease to (1.26) .
The company currently holds 2.75 M in liabilities with Debt to Equity (D/E) ratio of 0.03, which may suggest the company is not taking enough advantage from borrowing. Kempharm has a current ratio of 20.29, suggesting that it is liquid enough and is able to pay its financial obligations when due.
The market value of Kempharm is measured differently than its book value, which is the value of Kempharm that is recorded on the company's balance sheet. Investors also form their own opinion of Kempharm's value that differs from its market value or its book value, called intrinsic value, which is Kempharm's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Kempharm's market value can be influenced by many factors that don't directly affect Kempharm underlying business (such as pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Kempharm's value and its price as these two are different measures arrived at by different means. Investors typically determine Kempharm value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Kempharm's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Similar Executives

Found 2 records

CHAIRMAN Since

Marc TessierLavignecDenali Therapeutics
N/A
Arnold OronskyDynavax Technologies
2006
KemPharm, Inc., a specialty pharmaceutical company, discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company was incorporated in 2006 and is headquartered in Celebration, Florida. Kempharm operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 22 people. Kempharm (KMPH) is traded on NASDAQ Exchange in USA. It is located in 1180 Celebration Boulevard and employs 22 people. Kempharm was previously known as Kempharm and was traded on NASDAQ Exchange under the symbol KMPHD. Kempharm is listed under Pharmaceutical Products category by Fama And French industry classification.

Kempharm Leadership Team

Elected by the shareholders, the Kempharm's board of directors comprises two types of representatives: Kempharm inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Kempharm. The board's role is to monitor Kempharm's management team and ensure that shareholders' interests are well served. Kempharm's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Kempharm's outside directors are responsible for providing unbiased perspectives on the board's policies.
David Tierney, Independent Director
Sven Guenther, Executive Vice President -Research and Development
LaDuane Clifton, CFO
Joseph Saluri, Independent Director
Travis Mickle, Founder, Chairman, CEO and President and Member of Scientific and Medical Advisory Board
Timothy Sangiovanni, Principal Accounting Officer, Vice President Corporate Controller
Matthew Plooster, Independent Director
Gordon Johnson, Chief Bus. Officer
Richard Pascoe, Lead Independent Director
Danny Thompson, Independent Director

Kempharm Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Kempharm a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Kempharm Investors Sentiment

The influence of Kempharm's investor sentiment on the probability of its price appreciation or decline could be a good factor in your decision-making process regarding taking a position in Kempharm. The overall investor sentiment generally increases the direction of a stock movement in a one-year investment horizon. However, the impact of investor sentiment on the entire stock markets does not have a solid backing from leading economists and market statisticians.

Current Sentiment - KMPH

Kempharm Investor Sentiment

Most of Macroaxis users are now bullish on Kempharm. What is your trading attitude regarding investing in Kempharm? Are you bullish or bearish?
Bullish
Bearish
98% Bullish
2% Bearish
Skip

Becoming a Better Investor with Macroaxis

Macroaxis puts the power of mathematics on your side. We analyze your portfolios and positions such as Kempharm using complex mathematical models and algorithms, but make them easy to understand. There is no real person involved in your portfolio analysis. We perform a number of calculations to compute absolute and relative portfolio volatility, correlation between your assets, value at risk, expected return as well as over 100 different fundamental and technical indicators.

Build Optimal Portfolios

Align your risk with return expectations

Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations
Please see Stocks Correlation. Note that the Kempharm information on this page should be used as a complementary analysis to other Kempharm's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Portfolio Backtesting module to avoid under-diversification and over-optimization by backtesting your portfolios.

Complementary Tools for Kempharm Stock analysis

When running Kempharm price analysis, check to measure Kempharm's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Kempharm is operating at the current time. Most of Kempharm's value examination focuses on studying past and present price action to predict the probability of Kempharm's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Kempharm's price. Additionally, you may evaluate how the addition of Kempharm to your portfolios can decrease your overall portfolio volatility.
Portfolio Volatility
Check portfolio volatility and analyze historical return density to properly model market risk
Go
Cryptocurrency Center
Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency
Go
Premium Stories
Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope
Go
Instant Ratings
Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance
Go
Portfolio Rebalancing
Analyze risk-adjusted returns against different time horizons to find asset-allocation targets
Go
Financial Widgets
Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets
Go
Price Transformation
Use Price Transformation models to analyze depth of different equity instruments across global markets
Go
The market value of Kempharm is measured differently than its book value, which is the value of Kempharm that is recorded on the company's balance sheet. Investors also form their own opinion of Kempharm's value that differs from its market value or its book value, called intrinsic value, which is Kempharm's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Kempharm's market value can be influenced by many factors that don't directly affect Kempharm underlying business (such as pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Kempharm's value and its price as these two are different measures arrived at by different means. Investors typically determine Kempharm value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Kempharm's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.